Author: Customer Service

HOUSTON, June 10, 2026 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG), (the “Company”), a leader in providing controls infrastructure for subsea oil and gas fields, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 2:30pm (PST) at the Bellagio Resort & Hotel. Erik Wiik, President and CEO, and Kurt Keller, Chief Financial Officer, will deliver the presentation and host a question-and-answer session immediately following. To access the live presentation, please use the following information: Planet MicroCap Showcase: Vegas 2026Presentation Date: Wednesday, June 17, 2026Presentation Time: 2:30pm (PST)Location: Bellagio Resort & Hotel, Las Vegas, NV, in Track 5 – Raphael 2Webcast: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpUua92/mDujgDyHN9g7g7BSsHC5e7 If...

Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that the European Patent Office (EPO) has completed the technical preparations for the publication of the Company’s European patent application entitled “Mucoadhesive Polymers for Nasal Drug Delivery.” The application was published under European publication number EP 4751737. The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving...

Artelo’s lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London SOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicinal Chemist at Artelo, is delivering an oral presentation today highlighting encouraging metabolite identification and profiling data from the Company’s lead FABP inhibitor candidate, ART26.12, during the 7th RSC-BMCS/DMDG New Perspectives in DMPK and Medicinal Chemistry Conference, held at the Burlington House in London. The presentation features...

A&B Aerospace, SVM Machining, and AGA Precision Systems Position PMGC’s Precision Manufacturing Platform to Serve Growing Demand Across Satellites, Launch Systems, and Space Infrastructure, such as Space Data CentersNEWPORT BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), a diversified holding company, highlights that its current precision manufacturing operating subsidiaries currently serve and have the opportunity to further capitalize of the current Space exploration industry growth. PMGC’s wholly owned operating companies positioned to serve the space economy include A&B Aerospace, Inc. (“A&B Aerospace”), SVM Machining, Inc. (“SVM Machining”), and AGA Precision Systems LLC (“AGA Precision Systems”). With ITAR registration and AS9100...

TRESU INVESTMENT HOLDING A/SANNOUNCEMENT NO. 05.202610.06.2026 TRESU Investment Holding A/S – adjustment to full year 2026 guidance TRESU Investment Holding A/S today announces an adjustment to full year guidance for 2026 mainly driven by a market slowdown impacting especially the Machine & Units segment. Therefore, we are adjusting our expectations for full year 2026 revenue development to be in the range of -5% to -15% (previous guidance 0% to +10%) and the IFRS adjusted EBITDA margin remain unchanged in the range of +2% to +8%. Cash Flow is unchanged. Stephan PlenzCEO, TRESU For further details, please contact:CEO, Stephan Plenz, phone: +45 2194 5480CFO, Jesper Eriksen, phone: +45 6073 1967

Press Release dsm-firmenich receives FDA approval on PARSOL® Shield, a new sun protection ingredient for the U.S. Kaiseraugst (Switzerland), Maastricht (Netherlands), June 10, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announces the FDA approval of bemotrizinol (brand name: PARSOL® Shield) for the U.S. market, making it the first new sunscreen active ingredient approved in the United States in more than 25 years under modernized GRASE (Generally Recognized as Safe and Effective) and MUsT (Maximal Usage Trial) evaluation guidelines. The approval marks a major milestone for sunscreen innovation and public skin health in the United States, helping expand access to next-generation UV protection while opening new possibilities for formulators across the industry. Parand Salmassinia, Beauty & Care President at dsm-firmenich...

SINGAPORE, June 10, 2026 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), a medical clinic operator in Singapore, today announced that the Company’s board of directors has approved the consolidation of the Company’s issued and outstanding shares of the Company on a 1-for-12 ratio with the marketplace effective date of June 22, 2026. The objective of the reverse share split is to enable the Company to recomply with Nasdaq Marketplace Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1 per share. According to the law of the British Virgin Islands, the jurisdiction of the Company’s incorporation, and its memorandum and articles of association, no approval by shareholders and no amendment of the Company’s articles of association will be required for the reverse share split. Beginning...

Miami, FL, June 10, 2026 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced that its Board of Directors has declared a quarterly dividend of $0.15 per share, or $0.60 per share on an annualized basis, for the second quarter of 2026. Shareholders of record as of the close of business on June 30, 2026 will be paid a dividend of $0.15 on July 31, 2026. About TecnoglassTecnoglass Inc. is a leading producer of high-end aluminum and vinyl windows and architectural glass serving the multi-family, single-family, and commercial end markets. Tecnoglass is the second largest glass fabricator serving the U.S. and the #1 architectural glass...

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers VERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreated VERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formationNASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the...